Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Splenectomy | Research article

Risk evaluation of splenic hilar or splenic artery lymph node metastasis and survival analysis for patients with proximal gastric cancer after curative gastrectomy: a retrospective study

Authors: Peng Ding, Ziming Gao, Chen Zheng, Junqing Chen, Kai Li, Shan Gao

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

As splenectomy and spleen-preserving lymphadenectomy are performed only in some proximal gastric cancer patients, it is difficult to identify patients who have undergone radical gastrectomy with or without splenic hilar (No.10) or splenic artery (No.11) lymph node metastases. We aimed to determine the risk factors for No.10 and No.11 lymph node metastases and evaluate the survival significance of No.10 and No.11 lymph node dissection in advanced proximal gastric cancer patients.

Methods

A total of 873 advanced proximal gastric cancer patients who underwent curative gastrectomy with or without splenectomy or pancreaticosplenectomy were analyzed retrospectively. The clinicopathological characteristics of 152 patients who underwent splenectomy or pancreaticosplenectomy were analyzed to determine the risk factors for No.10 and No.11 lymph node metastases. The survival difference between patients with No.10 and No.11 lymph node dissections and those who did not undergo these dissections were compared.

Results

Patients with No.10 and No.11 lymph node metastases had very poor prognoses. Tumor invasion of the greater curvature and No.2 and No.4 lymph node metastases were independent risk factors for No.10 and No.11 lymph node metastases. No survival differences were evident between patients with No.10 and No.11 lymph node metastases who underwent No.10 and No.11 lymph node dissections and those who did not undergo these dissections but were at high risks of No.10 and No.11 lymph node metastases.

Conclusions

Splenic hilar or splenic artery lymph node dissection was not associated with increased survival, in proximal gastric cancer patients without direct cancer invasion of the spleen and pancreas, regardless of whether splenectomy, pancreaticosplenectomy, or spleen-preserving lymphadenectomy was performed.
Literature
1.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.CrossRef
2.
go back to reference LM B, SS D. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am. 2002;11:235–56. LM B, SS D. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am. 2002;11:235–56.
3.
go back to reference Borch DK, Jönsson B, Tarpila E, et al. Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. Br J Surg. 2000;87:618–26.CrossRef Borch DK, Jönsson B, Tarpila E, et al. Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. Br J Surg. 2000;87:618–26.CrossRef
4.
go back to reference Saito H, Fukumoto Y, Osaki T, et al. Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach. World J Surg. 2006;30:1864–9.CrossRef Saito H, Fukumoto Y, Osaki T, et al. Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach. World J Surg. 2006;30:1864–9.CrossRef
5.
go back to reference Gulmann C, Hegarty H. AntoinetteGrace, et al. differences in proximal (cardia) versus distal (antral) gastric carcinogenesis via retinoblastoma pathway. World J Gastroenterol. 2004;10:17–21.CrossRef Gulmann C, Hegarty H. AntoinetteGrace, et al. differences in proximal (cardia) versus distal (antral) gastric carcinogenesis via retinoblastoma pathway. World J Gastroenterol. 2004;10:17–21.CrossRef
6.
go back to reference Zhang CH, Zhan WH, He YL, et al. Spleen preservation in radical surgery for gastric cardia cancer. Ann Surg Oncol. 2007;14:1312–9.CrossRef Zhang CH, Zhan WH, He YL, et al. Spleen preservation in radical surgery for gastric cardia cancer. Ann Surg Oncol. 2007;14:1312–9.CrossRef
7.
go back to reference Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg. 2006;93:559–63.CrossRef Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg. 2006;93:559–63.CrossRef
8.
go back to reference Sano T, Sasako M, Mizusawa J, et al. Randomized controlled trial to evaluate splenectomy in Total gastrectomy for proximal gastric carcinoma. Ann Surg. 2017;265:277–83.CrossRef Sano T, Sasako M, Mizusawa J, et al. Randomized controlled trial to evaluate splenectomy in Total gastrectomy for proximal gastric carcinoma. Ann Surg. 2017;265:277–83.CrossRef
9.
go back to reference Otsuji E, Yamaguchi T, Sawai K, et al. Total gastrectomy with simultaneous pancreaticosplenectomy or splenectomy in patients with advanced gastric carcinoma. Br J Cancer. 1999;79:1789–1793.CrossRef Otsuji E, Yamaguchi T, Sawai K, et al. Total gastrectomy with simultaneous pancreaticosplenectomy or splenectomy in patients with advanced gastric carcinoma. Br J Cancer. 1999;79:1789–1793.CrossRef
10.
go back to reference Shin SH, Jung H, Choi SH, et al. Clinical significance of splenic hilar lymph node metastasis in proximal gastric cancer. Ann Surg Oncol. 2009;16:1304–9.CrossRef Shin SH, Jung H, Choi SH, et al. Clinical significance of splenic hilar lymph node metastasis in proximal gastric cancer. Ann Surg Oncol. 2009;16:1304–9.CrossRef
11.
go back to reference Sasada S, Ninomiya M, Nishizaki M, et al. Frequency of lymph node metastasis to the splenic hilus and effect of splenectomy in proximal gastric cancer. Anticancer Res. 2009;29:3347–3351. Sasada S, Ninomiya M, Nishizaki M, et al. Frequency of lymph node metastasis to the splenic hilus and effect of splenectomy in proximal gastric cancer. Anticancer Res. 2009;29:3347–3351.
12.
go back to reference Li F, Zhang R, Liang H, et al. The pattern and risk factors of recurrence of proximal gastric cancer after curative resection. J Surg Oncol. 2013;107:130–5.CrossRef Li F, Zhang R, Liang H, et al. The pattern and risk factors of recurrence of proximal gastric cancer after curative resection. J Surg Oncol. 2013;107:130–5.CrossRef
13.
go back to reference Norouzinia M, Asadzadeh H, Shalmani HM, et al. Clinical and histological indicators of proximal and distal gastric Cancer in eight provinces of Iran. Asian Pac J Cancer Prev. 2012;13:5677–9.CrossRef Norouzinia M, Asadzadeh H, Shalmani HM, et al. Clinical and histological indicators of proximal and distal gastric Cancer in eight provinces of Iran. Asian Pac J Cancer Prev. 2012;13:5677–9.CrossRef
14.
go back to reference Aoyagi K, Kouhuji K, Miyagi M, et al. Prognosis of metastatic splenic hilum lymph node in patients with gastric cancer after total gastrectomy and splenectomy. World J Hepatol. 2010;2:81–6.CrossRef Aoyagi K, Kouhuji K, Miyagi M, et al. Prognosis of metastatic splenic hilum lymph node in patients with gastric cancer after total gastrectomy and splenectomy. World J Hepatol. 2010;2:81–6.CrossRef
15.
go back to reference Bian S, Xi H, Wu X, et al. The role of no. 10 lymphadenectomy for advanced proximal gastric Cancer patients without metastasis to no. 4sa and no. 4sb lymph nodes. J Gastrointest Surg. 2016;20:1295–304.CrossRef Bian S, Xi H, Wu X, et al. The role of no. 10 lymphadenectomy for advanced proximal gastric Cancer patients without metastasis to no. 4sa and no. 4sb lymph nodes. J Gastrointest Surg. 2016;20:1295–304.CrossRef
16.
go back to reference Takahashi T, Sawai K, Hagiwara A, et al. Type-oriented therapy for gastric cancer effective for lymph node metastasis: management of lymph node metastasis using activated carbon particles adsorbing an anticancer agent. Semin Surg Oncol. 2010;7:378–83.CrossRef Takahashi T, Sawai K, Hagiwara A, et al. Type-oriented therapy for gastric cancer effective for lymph node metastasis: management of lymph node metastasis using activated carbon particles adsorbing an anticancer agent. Semin Surg Oncol. 2010;7:378–83.CrossRef
17.
go back to reference Yang K, Zhang WH, Chen XZ, et al. Survival benefit and safety of no. 10 lymphadenectomy for gastric cancer patients with total gastrectomy. Medicine (Baltimore). 2014;93:e158.CrossRef Yang K, Zhang WH, Chen XZ, et al. Survival benefit and safety of no. 10 lymphadenectomy for gastric cancer patients with total gastrectomy. Medicine (Baltimore). 2014;93:e158.CrossRef
Metadata
Title
Risk evaluation of splenic hilar or splenic artery lymph node metastasis and survival analysis for patients with proximal gastric cancer after curative gastrectomy: a retrospective study
Authors
Peng Ding
Ziming Gao
Chen Zheng
Junqing Chen
Kai Li
Shan Gao
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-6112-4

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine